Written by Richard Daverman, PhD, Executive Editor, Greg B. Scott.

Recent
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010

Click a link below to view the mailing archive as if it had been sent to you.

2019-11-20 01:303SBio and Verseau Choose First Candidate in Microphage Immunotherapy Partnership and more...
2019-11-19 01:30Novartis Refocuses Shanghai Research Institute on Drug Development, not Discovery and more...
2019-11-17 01:30Week in Review: BeiGene's BTK Inhibitor Approved in US and China Approval for PD-1 Expected in Two Months
2019-11-16 01:30China's Glut of PD-1/PD-L1 Candidates -- How Can They All Find a Market? and more...
2019-11-15 01:30BeiGene's PD-1 Recommended for Approval by China's CDE and more...
2019-11-14 01:30Shanghai Anovent Closes Funding Led by Sequoia for Respiratory Drugs
2019-11-13 01:30Hua Reports Positive Phase III Data for Novel Type 2 Diabetes Drug and more...
2019-11-12 01:30Hengrui Acquires Rights to Novaliq Dry Eye Treatments in $165 Million Deal and more...
2019-11-10 01:30Week in Review: AstraZeneca Announces $1 Billion Fund for China Life Science Startups
2019-11-09 01:30CStone's PD-L1 Candidate Shows Positive Results for Lymphoma
2019-11-08 01:30Tot Biopharm Completes $66.5 Million Hong Kong IPO and more...
2019-11-07 01:30Peijia Medical Raises $100 Million for Medical Device Development and more...
2019-11-06 01:30AstraZeneca Plans $1 Billion Fund for China Biopharma Startups and more...
2019-11-05 01:30Shanghai Green Valley Surprises with China Approval for Alzheimer's Treatment and more...
2019-11-03 01:30Week in Review: BeiGene Forms Blockbuster $2.7 Billion Collaboration with Amgen
2019-11-02 01:30QYuns Out-Licenses Ex-China Rights for Autoimmune Portfolio to Seneca
2019-11-01 01:30Amgen to Make $2.7 Billion Investment in BeiGene; BeiGene to Develop 23 Amgen Candidates in China and more...

Please enter all required fields Click to hide
Correct invalid entries Click to hide
 

Subscribe >>


Not a ChinaBio®Today Subscriber?

Here's what you get with a paid subscription to ChinaBio® Today:
  • Website access to all current articles and commentary
  • Full access to over 2000 archived articles on the biotech industry

Greg B. Scott
Executive Editor
ChinaBio® Today


ChinaBio and ChinaBio Today are trademarks of ChinaBio LLC